ImmunID Technologies : Service Research Contract with Sanofi Pasteur

January 14, 2008 - ImmunID Technologies announced the signature of a Contract Research Service with Sanofi Pasteur, the vaccines division of sanofi-aventis Group, and the largest worldwide company entirely devoted to human vaccines.
The innovative technology developed by ImmunID allows the assessment of Human T and B immune repertoires diversity after vaccination...


...About ImmunID
ImmunID Technologies is a young Biotechnology company located in Grenoble, its mission is to develop and commercialise immunomonitoring tests dedicated to pharmaceutical industry and personalized medicine market.
ImmunID offers testing services to monitor the immune repertoire diversity in order to measure the impact of biotherapeutic molecules and to characterize more accurately their efficacy.
ImmunID develops diagnostic products for an early detection of immune related diseases... [PDF] ImmunID Technologies' Press Release -

Sanofi-aventis : Phase III Results for Eplivanserin

April 30, 20008 - ... Eplivanserin : Sanofi-aventis announced today that the GEMS Phase III study shows that the 5-HT2A antagonist eplivanserin in development for the treatment of insomnia characterized by sleep maintenance difficulties/night- time awakenings significantly reduces WASO (Wake time After Sleep Onset) and the number of night-time awakenings reported by the patient at 6 and 12 weeks of treatment, versus placebo. An improvement of the quality of sleep was also observed in the study.These results confirm those of the EPLILONG study (phase III study conducted in similar conditions), which also showed that eplivanserin significantly reduces WASO and the number of night-time awakenings reported by the patient at 6 and 12 weeks, versus placebo and improves the quality of sleep... [PDF] Sanofi-aventis' Press Release - PDF du Communiqué de Presse de Sanofi-Aventis -

UCB and sanofi-aventis, FDA Approves XYZAL® (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies

February 19, 2008 - UCB and sanofi-aventis announced that the U.S. Food and Drug Administration (FDA) approved a New Drug Application (NDA) for XYZAL® (levocetirizine dihydrochloride) 0.5 mg/mL oral solution, a prescription antihistamine indicated for the relief of symptoms associated with indoor and outdoor allergies, as well as the treatment of chronic idiopathic urticaria. XYZAL® tablets received FDA approval on May 25, 2007 and both formulations are now approved for use in adults and children 6 years and older...Many people suffer from the symptoms associated with common allergic conditions. The immune system of allergy sufferers over-reacts to something in the environment, leading to symptoms that affect their respiratory system, eyes, or skin. Estimates from the American Academy of Allergy, Asthma & Immunology (AAAAI) suggest that indoor and outdoor allergies affect as many as 40 million people in the United States... UCB's press Release- [PDF] sanofi-aventis' Press release- PDF du Communiqué de Presse de sanofi-aventis-